

Agency for Healthcare Research and Quality Advancing Excellence in Health Care • www.ahrq.gov

2014 NAPCRG PBRN Conference June 30, 2014

Improvement and Innovation Networks

The Intersection between Research and Quality Improvement

Lloyd Provost Associates in Process Improvement Iprovost @apiweb.org

API - 2014

The Collaborative Knowledge Networks







Peter Gloor MIT Center for Collective Intelligence



PETER A. GLOOR



Effective networks for improvement

Developing and managing effective networks to support quality improvement in healthcare



Learning report March 2014



http://www.health.org.uk/publications/effective?hetworks-for-improvement/

AHRE Learning Healthcare System

- Patients and providers work together to choose care based on best evidence
- Drive discovery as natural outgrowth of patient care
- Ensure innovation, quality, safety and value
- All in real-time

THE LEARNING HEALTHCARE SYSTEM

Workshop Summary





Components of a network-based Learning Health System*

- Focus on outcome
- Build community
- Effective use of technology
- Learning system

System science, quality improvement, qualitative research, clinical research



ImproveCareNow is an Example of an Improvement Network

Purpose of ImproveCareNow (ICN):

Transform the health, care and costs for all children and adolescents with Crohn's disease and ulcerative colitis by building a sustainable collaborative chronic care network, enabling patients, families, clinicians and researchers to work together in a learning health care system to accelerate innovation, discovery and the application of new knowledge.

September 2012, first organized in 2005

Richard Colletti, MD and Peter Margolis, MD, PhD. Supported by: NIH NIDDK R01DK085719, AHRQ R01HS020024, AHRQ U18HS016957, PCORI PPRN-1306-01754, ImproveCareNow Network Care Centers, CCHMC Learning Networks Program

AHRE The ImproveCareNow Story

- ImproveCareNow has improved care and outcomes for children without new medications.
- Patients partnered with researchers and providers to innovate within this Learning Health System.
- The network works continuously to build a community to motivate and support providers, researchers, and patients.
- Through a quality improvement network, ICN has changed patients lives.



Number of centers in ICN

(Thru the 3rd quarter of 2013)



Geographic Reach of Аннас ImproveCareNow Network, 2014



ImproveCareNow, 2014

API - 2014



Aggregate Improvement in Outcomes



ImproveCareNow, 2014

Learning from Variation among Centers



Some ICN Publications

ImproveCareNow: The Development of a Pediatric Inflammatory Bowel Disease Improvement Network

Wallace Crandall, MD,¹ Michael D. Kappelman, MD, MPH,² Richard B. Colletti, MD,³ Ian Leibowitz, MD,⁴ John E. Grunow, MD,⁵ Sabina Ali, MD,⁶ Howard I. Baron, MD,⁷ James H. Berman, MD,⁸ Brendan Boyle, MD,¹ Stanley Cohen, MD,⁹ Fernando del Rosario, MD,¹⁰ Lee A. Denson, MD,¹¹ Lynn Duffy, MD,⁴ Mark J. Integlia, MD,¹² Sandra C. Kim, MD,² David Milov, MD,¹⁰ Ashish S. Patel, MD,¹³ Bess T. Schoen, MD,⁹ Dorota Walkiewicz, MD,¹⁴ and Peter Margolis, MD, PhD¹⁵ Inflamm Bowel Dis • Volume 17, Number 1, January 2011

Improved Outcomes in a Quality Improvement Collaborative for Pediatric Inflammatory Bowel Disease

Wallace V. Crandall, Peter A. Margolis, Michael D. Kappelman, Eileen C. King, Jesse M. Pratt, Brendan M. Boyle, Lynn F. Duffy, John E. Grunow, Sandra C. Kim, Ian Leibowitz, Bess T. Schoen, Richard B. Colletti and for the ImproveCareNow Collaborative *Pediatrics* 2012;129;e1030; originally published online March 12, 2012;

Collaborative Chronic Care Networks (C3Ns) to Transform Chronic Illness Care

Peter A. Margolis, Laura E. Peterson and Michael Seid *Pediatrics* 2013;131;S219 DOI: 10.1542/peds.2012-3786J APT-2014

Improving Outcomes with a Learning Health System



AHRR





ImproveCareNow, 2014



The ICN2 Registry

Data are entered in real time or close to real time during the visit and in many centers are being uploaded right from the electronic record. Visit records contain 80 variables describing that patient and their care.

📝 IBD Registry					
Background information					
Current diagnosis					
Crohn's disease	ulcerative colitis	indeterminate colitis			
Has the patient had a complete colectomy? (If correct information appears in the sidebar, it is okay to leave this response blank.)					
Does the patient currently I colostomy?	nave an ileostomy or	Yes No 🗖 unknown			
Current symptoms					
Describe the IBD sympton	ns on the WORST day	in the last 7 days:			
General well-being					
normal fair	poor unknow	1			
Limitations in daily activitie	s				
no limitations	casional frequent	unknown			
Abdominal pain					
none	mild	moderate to severe	unknown		
Stool characteristics					
Describe the stools on the	WORST day in the la	st7 days:			
Total number of stools		3.0 🔢 🗆 not available/a	assessed		
Most stools were	formed	partially formed	watery	unknown	
Number of liquid/watery sto	ols per day (O if none)	1.0 📓 🗖 not available/a	assessed		
Did the patient report blood	y stools?	Yes No 🗖 unknown			
The typical amount of blood	1 was				
small amount in <509	% of stools small at	nount in >=50% of stools			
large amour	nt	unknown			
Did the patient report noctu	ırnal diarrhea?	Yes No 🗖 unknown			
Extraintestinal manifestat	ions (current)				
Fever >38.5 C for 3 of the la	ast 7 days?	Yes No 🗆 unknown			
Definite arthritis?		Yes No 🗆 unknown			
Â	PI - 2014				15

Richard Colletti, M, Keith Marsolo, PhD



Registry: Management of Patient Population

ICN - Population Management Report

Page 1 of 7

<-- Back to ICN Reports

Data as of 11/26/2013

Nationwide Children's Hospital

DX: Crohns Disease, Indeterminate Colitis, Ulcerative Colitis

Care Stratification Score



	12 Month Disease Activity - CSS (n and %)
0 (Quiescent)	454
<u>1 (Mild)</u>	56
2 (Moderate or Severe)	47
Total	557



	Care Stratification Score (n and %)
0-3 (Low)	456
4-9 (High)	96
>=10 (Critical)	5
Total	557

ImproveCareNow, 2014



Learning for Improvement (QI) Care Center Performance Report





Growth status						
	satisfactory	at risk	in failu	ıre	not assessed	
Adherence assessment			Drop in height by 2 isobars; OR height below 3rd percentile for age; OR height velocity below 3rd			
	satisfa	ctory		percer	ntile	

Assessments

Physician's global assessment of current disease status

	quiescent	mild modera	severe	unknown		
Nutritional status			Moderate pain; moderate diarrhea, including			
	satisfactory	actory at risk active fistula; significant weight loss and/or abdom tenderness; non-toxic; significant lab abnormalities				
Gre	with status					





Care Center Level Studies

						% in Remission
(Treatment Combination	Pre-visit Planning	Population Management	Self- Management Support	Aug RR 85.00	Run Order for: Aug RR
	Site 1	-	-	-	83.00 81.00	. (
	Site 2	+	-	-	79.00 77.00	•
	Site 3	-	+	-	75.00 73.00	• • •
	Site 4	-	-	+	71.00	\bigcirc
	Site 5	+	-	+	69.00 67.00	\mathbf{O}
	Site 6	-	+	+	65.00 ^L	1 2 3 4 5 6 7
	Site 7	+	+	-		Run Order Plot
	Site 8	+	+	+		



One Research area: Personalized Learning System

19 yr. old with Crohn's colitis Colectomy with ileo-anal anastomosis (10 yrs) Chronic diarrhea, nocturnal stools, fatigue, poor quality of life Current medications: Infliximab & PRN imodium



Heather Kaplan, MD, MPH, Jeremy Adler, MD, MPH, Shehzad Saeed, MD, Ian Eslick, MS, Lloyd Provost, MS, Tom Nolan, PhD, Peter Margolis, MD, PhD



The NEW ENGLAND JOURNAL of MEDICINE

N ENGL J MED 362;15 NEJM.ORG APRIL 15, 2010

ORIGINAL ARTICLE

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

Jean Frédéric Colombel, M.D., William J. Sandborn, M.D., Walter Reinisch, M.D., Gerassimos J. Mantzaris, M.D., Ph.D., Asher Kornbluth, M.D.,
Daniel Rachmilewitz, M.D., Simon Lichtiger, M.D., Geert D'Haens, M.D., Ph.D., Robert H. Diamond, M.D., Delma L. Broussard, M.D., Kezhen L. Tang, Ph.D., C. Janneke van der Woude, M.D., Ph.D., and Paul Rutgeerts, M.D., Ph.D., for the SONIC Study Group*

SONIC Study

Methods

In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy, azathioprine monotherapy, and the two drugs combined in 508 adults with moderate-to-severe Crohn's disease who had not undergone previous immunosuppressive or biologic therapy.

CONCLUSIONS

Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or infliximab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azathioprine monotherapy. (ClinicalTrials.gov number, NCT00094458.) Anti-TNF antibodies - 1993

5 years later FDA approval for Crohn's disease - 1998

14 years later – 1st pediatric controlled clinical trial → REACH - 2007

But....treatment effects estimated without a comparison group

nicade

ImproveCareNow, 2014

API - 2014

Replicating the SONIC RCT using AHRR **ICN Registry**

PEDIATRICS Volume 134, Number 1, July 2014 Effectiveness of Anti-TNF α for Crohn Disease: Research in a Pediatric Learning Health System

AUTHORS: Christopher B. Forrest, MD, PhD,^{a,b} Wallace V. Crandall, MD,^c L. Charles Bailey, MD, PhD,^{a,d} Peixin Zhang, PhD,^a Marshall M. Joffe, MD, MPH, PhD,^d Richard B. Colletti, MD,^e Jeremy Adler, MD,^f Howard I. Baron, MD,^g James Berman, MD,^h Fernando del Rosario, MD,ⁱ Andrew B. Grossman, MD,^j Edward J. Hoffenberg, MD,^k Esther J. Israel, MD,¹ Sandra C. Kim, MD,^c Jenifer R. Lightdale, MD, MPH,^m Peter A. Margolis, MD, PhD,ⁿ Keith Marsolo, PhD,^{o,p} Devendra I. Mehta, MD, MS, MRCP.^q David E. Milov, MD,^r Ashish S. Patel, MD,st Jeanne Tung, MD,^u and Michael D. Kappelman, MD, MPH^v



WHAT THIS STUDY ADDS: Anti-TNF α therapy administered to children who have Crohn disease in routine practice settings was more effective than usual care at achieving clinical and corticosteroid-free remission. Using data from the ImproveCareNow learning health system for the purpose of observational research is feasible and produces valuable new knowledge.

This study provides evidence that anti-TNFa therapy given to pediatric patients who have moderate to severe CD in real-world settings is effective at achieving remission at rates comparable to single-group, open-label clinical trials, such as REACH,4 with pediatric patients and comparative controlled studies done with adults, such as SONIC.6 24



Replicating the SONIC RCT using ICN Registry

- Applying REACH selection criteria to the ICN sample yielded an average of 75 initiator trials across the 100 replicates.
- The approach we used in this study to examine observational registry data as a sequence of nonrandomized trials is a promising methodology that can be extended to other clinical questions.
- The method allows generalization of likely benefits to patients as it avoids overly strict selection criteria that characterize explanatory clinical trials, which test efficacy and are not representative of real-world practice.

Improving Outcomes with a Learning Health System



AHRR